Last reviewed · How we verify

Relative Bioavailability of Dabigatran After Administration of Different Application Forms of a Single Oral Dose of 150 mg Dabigatran Etexilate (Capsule, Powder for Reconstitution Into Solution, Pellets on Food) in Healthy Male and Female Volunteers (an Open-label, Randomised, Three-way Crossover, Clinical Phase I Study)

NCT02171611 Phase 1 COMPLETED Results posted

To determine the relative bioavailability of 150 mg of dabigatran etexilate as pellets on food and of 150 mg of dabigatran etexilate as powder resolved in reconstitution solution, both with 150 mg of dabigatran etexilate as capsule in healthy volunteers

Details

Lead sponsorBoehringer Ingelheim
PhasePhase 1
StatusCOMPLETED
Enrolment30
Start date2009-03

Conditions

Interventions

Primary outcomes